Allucent (UK)
Allucent (UK) is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
Sponsor Merz Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Subjects were recruited at 10 investigative sites in Poland, Ukraine, and Türkiye.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease
Sponsor H. Lundbeck A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs.
Sponsor Debiopharm International S.A.
- Start (EU)
- Latest update
- Estimated end
MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial
Sponsor HZRM Haemophilie-Zentrum Rhein Main GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Allucent (UK)?
The 2026-10-09 snapshot links Allucent (UK) to 4 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Regulatory services, CRO responsibilities, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Allucent (UK)?
The most frequently recorded therapeutic areas are Endocrinology, Neurology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Allucent (UK) conducted?
The linked trials record locations in 19 countries, including Spain, Poland, Bulgaria, Germany, France. These are trial locations, not confirmed office locations or countries where Allucent (UK) delivered services.
What can this page tell me about Allucent (UK)'s trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Allucent (UK). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Allucent (UK) Limited